Ibogaine & alcohol use disorder · through 2026

Research Tracker

A living summary of the limited and evolving evidence on ibogaine, noribogaine, and oxa-noribogaine for alcohol use disorder—what has been studied, what remains untested, and where caution belongs.

The landscape is early, uneven, and worth reading carefully.

Alcohol use disorder is a clinical diagnosis with established treatments, as described by the National Institute on Alcohol Abuse and Alcoholism’s overview of alcohol use disorder. Ibogaine research sits outside the standard evidence base: reports and small studies can be meaningful signals, but they do not substitute for controlled trials or individualized medical care.

Completed human evidence · limited

Observational signals, not a settled answer

Published human work involving ibogaine has focused more often on opioid use, treatment settings, safety, and broad substance-use outcomes than on alcohol use disorder as a primary, well-controlled target. A dedicated completed randomized trial establishing ibogaine’s efficacy for alcohol use disorder was not identified in this tracker.

Study aim and design: available human reports tend to be uncontrolled, follow people in nonstandard settings, or include mixed substance-use histories. That leaves sample definition, comparator conditions, follow-up, and alcohol-specific endpoints inconsistent.

Plain-language takeaway: personal accounts and uncontrolled observations may justify further study, but they cannot show whether an intervention caused a reduction in drinking, how durable any change was, or for whom risk may outweigh benefit.

Biology · context, not proof

Why metabolites are being watched

Ibogaine is converted to noribogaine, a longer-lasting metabolite that has drawn attention in pharmacology research. Oxa-noribogaine is a distinct investigational compound intended to separate some desired pharmacology from ibogaine’s more concerning properties.

These compounds should not be treated as interchangeable. Their chemistry, receptor activity, dosing, safety profile, and human evidence can differ.

Trial registries · status matters

Registered studies require close reading

Registry entries can identify a study’s aim, planned enrollment, design, endpoints, recruitment status, and sponsor. They do not establish results. The ClinicalTrials.gov registry is a useful primary starting point for checking whether a study is recruiting, completed, or has posted results.

Plain-language takeaway: a listed trial is a plan or record—not evidence of benefit. Completed studies may still have no public results, and unpublished outcomes should not be assumed.

Research scope · alcohol-specific

What a useful alcohol study would measure

A strong study would define alcohol use disorder clearly, specify baseline drinking, monitor abstinence and heavy-drinking days over meaningful follow-up, document co-occurring conditions and treatments, and use a credible comparison group. Safety monitoring would need to be central rather than incidental.

For practical context beyond this tracker, the broader ibogaine and alcohol treatment guide separates research interest from clinical decision-making.

What the existing evidence can—and cannot—support.

A dedicated, completed randomized controlled trial demonstrating ibogaine efficacy for alcohol use disorder was not identified here. Absence of such a trial is not proof of no effect; it is a limit on what can be concluded.

Safety is a research endpoint.

Ibogaine has been associated with potentially dangerous cardiac effects, including QT interval prolongation. The FDA discussion of QT prolongation and abnormal heart rhythms illustrates why this electrical effect is treated seriously in drug safety, even though it addresses a different medicine.

Alcohol withdrawal, other medicines, electrolyte disturbances, and health history may further complicate risk assessment. The page on ibogaine safety considerations with alcohol addresses these issues in more detail.

PRECLINICAL
Animal and laboratory findings can point to mechanisms or future hypotheses, but do not predict clinical benefit reliably.

HUMAN STUDY
Small or uncontrolled work can establish feasibility signals and reveal harms; it cannot reliably establish comparative efficacy.

RCT
Randomization, controls, prespecified endpoints, and follow-up are needed to reduce bias and test whether an effect holds up.

Compounds, milestones, and the questions still open.

Ibogaine is an indole alkaloid derived from Tabernanthe iboga; the general ibogaine reference entry is useful for basic context, but primary papers and registry records matter more when assessing a specific alcohol-related claim.

Ibogaine

Historical interest meets a difficult safety profile.

Ibogaine has generated longstanding interest across substance-use contexts. For alcohol use disorder specifically, the central unanswered question is whether potential changes in craving or drinking can be demonstrated in appropriately controlled human research while managing serious risk.

In the United States, ibogaine remains a Schedule I controlled substance, a regulatory status that shapes access and research pathways.

Noribogaine

A metabolite with its own research rationale

Noribogaine persists longer than ibogaine and has been investigated as part of the broader attempt to understand which pharmacologic actions may relate to substance-use outcomes. For alcohol use disorder, the key gaps are alcohol-specific clinical trials, dose-ranging work, safety characterization, and durable outcome data.

Design needed: randomized comparison, blinded assessment where feasible, carefully defined alcohol endpoints, medication and withdrawal screening, ECG monitoring, and adequate follow-up after dosing.

Oxa-noribogaine

An investigational attempt to change the risk-benefit question

Oxa-noribogaine is being studied as a related compound with a different pharmacologic profile from ibogaine. Its development does not validate ibogaine for alcohol use disorder, and preclinical or early-stage findings should not be presented as evidence of alcohol-treatment effectiveness.

Plain-language takeaway: a new analogue may be scientifically important, but it remains necessary to see alcohol-specific human data, transparent safety reporting, and peer-reviewed results.

Regulatory milestone

Legal status does not answer the clinical question.

Regulatory classification affects research and access; it does not determine whether a compound works or is safe for a particular condition. The DEA explanation of drug scheduling provides the federal framework for understanding why study routes can be constrained.

People comparing international options may encounter provider claims; the Tijuana clinic information page is best read alongside independent scrutiny of evidence and safety, not as proof of efficacy.

Next-step research

The questions a credible program must answer.

What would a meaningful randomized trial look like?

It would enroll people with clearly defined alcohol use disorder, state eligibility and exclusion criteria, compare a planned intervention against an appropriate control, prespecify drinking and safety endpoints, and follow participants long enough to assess durability. It would also report adverse events in enough detail to judge whether harms cluster in particular groups.

Why are safety studies not a side issue?

They are essential. Any alcohol-focused research needs careful screening for cardiac risk, drug interactions, electrolyte abnormalities, liver and other health factors, and alcohol withdrawal risk. This is one reason an overview of ibogaine detox centers should never be mistaken for a clinical evidence base or a guarantee of appropriate medical safeguards.

How should people interpret claims of success?

Ask whether a claim comes from a registered protocol, peer-reviewed results, a controlled design, alcohol-specific outcomes, and clearly reported follow-up. Testimonials cannot distinguish treatment effects from selection, expectation, simultaneous care, or natural changes in drinking. Research on other conditions should be kept separate too; for example, claims about ibogaine and Parkinson’s-related topics do not answer the alcohol use disorder question.

What belongs on the tracker next?

New peer-reviewed alcohol-specific trials, posted registry results, pharmacokinetic studies, adverse-event reporting, and regulator communications are all more informative than promotional language. Related research areas should remain distinct: discussions of ibogaine for PTSD treatment may be relevant to co-occurring conditions, but they are not evidence for alcohol outcomes. Cost discussions likewise require care; the ibogaine cost overview concerns access and pricing claims, not demonstrated effectiveness.

Keep the question proportional to the evidence.

Use this tracker to distinguish active research from established treatment, then return to the wider Ember Vale alcohol and ibogaine research resource for carefully framed context. For questions about the project’s approach, its independent evidence-first principles explain how uncertainty and safety are handled.

Review safety context